Literature DB >> 20452430

Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use.

Henry R Shinefield1.   

Abstract

Glycoconjugate vaccines have been proven safe and effective against various diseases in children. Although these vaccines have a history of effectiveness, there are still many unanswered questions to be addressed, including conjugate interference when multiple vaccines are administered at one time, expansion of serotype coverage, effectiveness in special populations, and issues relating to conjugate vaccine use in the developing world. This paper focuses on the use of CRM(197) as a carrier protein, contrasting it to other carrier proteins used in single-antigen pediatric vaccines as well as identifying areas for future study.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20452430     DOI： 10.1016/j.vaccine.2010.04.072

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  31 in total

1.  Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.

Authors:  Barb Lohman-Payne; Jennifer Slyker; Sarah L Rowland-Jones
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

2.  Synthesis of multivalent glycopeptide conjugates that mimic an HIV epitope.

Authors:  Jennifer K Bailey; Dung N Nguyen; Satoru Horiya; Isaac J Krauss
Journal:  Tetrahedron       Date:  2016-07-29       Impact factor: 2.457

3.  Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.

Authors:  Rashmi Jalah; Oscar B Torres; Alexander V Mayorov; Fuying Li; Joshua F G Antoline; Arthur E Jacobson; Kenner C Rice; Jeffrey R Deschamps; Zoltan Beck; Carl R Alving; Gary R Matyas
Journal:  Bioconjug Chem       Date:  2015-06-05       Impact factor: 4.774

4.  Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197.

Authors:  Enrico Malito; Badry Bursulaya; Connie Chen; Paola Lo Surdo; Monica Picchianti; Enrico Balducci; Marco Biancucci; Ansgar Brock; Francesco Berti; Matthew James Bottomley; Mikkel Nissum; Paolo Costantino; Rino Rappuoli; Glen Spraggon
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

Review 5.  High-affinity anti-glycan antibodies: challenges and strategies.

Authors:  Zinaida Polonskaya; Paul B Savage; M G Finn; Luc Teyton
Journal:  Curr Opin Immunol       Date:  2019-04-28       Impact factor: 7.486

6.  Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus.

Authors:  Adam C Finnefrock; Daniel C Freed; Aimin Tang; Fengsheng Li; Xi He; Chengwei Wu; Debbie Nahas; Dai Wang; Tong-Ming Fu
Journal:  Hum Vaccin Immunother       Date:  2016-03-17       Impact factor: 3.452

7.  A Semi-Synthetic Glycoconjugate Vaccine Candidate for Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Peter H Seeberger; Claney L Pereira; Naeem Khan; Guozhi Xiao; Elizabeth Diago-Navarro; Katrin Reppe; Bastian Opitz; Bettina C Fries; Martin Witzenrath
Journal:  Angew Chem Int Ed Engl       Date:  2017-10-05       Impact factor: 15.336

8.  Chemical synthesis of the outer core oligosaccharide of Escherichia coli R3 and immunological evaluation.

Authors:  Wenjing Shang; Zhongying Xiao; Zaikuan Yu; Na Wei; Guohui Zhao; Qing Zhang; Mohui Wei; Xuan Wang; Peng George Wang; Tiehai Li
Journal:  Org Biomol Chem       Date:  2015-03-12       Impact factor: 3.876

9.  Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.

Authors:  Ivette Caro-Aguilar; Elizabeth Ottinger; Robert W Hepler; Deborah D Nahas; Chengwei Wu; Michael F Good; Michael Batzloff; Joseph G Joyce; Jon H Heinrichs; Julie M Skinner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

Review 10.  Heparin-binding Peptides as Novel Therapies to Stop SARS-CoV-2 Cellular Entry and Infection.

Authors:  Omid Tavassoly; Farinaz Safavi; Iman Tavassoly
Journal:  Mol Pharmacol       Date:  2020-09-10       Impact factor: 4.436
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.